LUMEXA IMAGING HOLDINGS INC (LMRI) Fundamental Analysis & Valuation

NASDAQ:LMRI • US5502491062

Current stock price

9.71 USD
+0.11 (+1.15%)
At close:
9.6 USD
-0.11 (-1.13%)
Pre-Market:

This LMRI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LMRI Profitability Analysis

1.1 Basic Checks

  • In the past year LMRI has reported negative net income.
  • LMRI had a positive operating cash flow in the past year.
LMRI Yearly Net Income VS EBIT VS OCF VS FCFLMRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • LMRI has a worse Return On Assets (-2.67%) than 62.00% of its industry peers.
  • LMRI's Return On Equity of -8.04% is on the low side compared to the rest of the industry. LMRI is outperformed by 60.00% of its industry peers.
  • LMRI has a Return On Invested Capital of 1.33%. This is in the lower half of the industry: LMRI underperforms 60.00% of its industry peers.
Industry RankSector Rank
ROA -2.67%
ROE -8.04%
ROIC 1.33%
ROA(3y)-5.2%
ROA(5y)N/A
ROE(3y)-42.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMRI Yearly ROA, ROE, ROICLMRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • LMRI has a Operating Margin (2.61%) which is comparable to the rest of the industry.
  • Looking at the Gross Margin, with a value of 15.40%, LMRI is doing worse than 62.00% of the companies in the same industry.
Industry RankSector Rank
OM 2.61%
PM (TTM) N/A
GM 15.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMRI Yearly Profit, Operating, Gross MarginsLMRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025 0 5 -5 10 -10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. LMRI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LMRI is destroying value.
  • LMRI has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, LMRI has an improved debt to assets ratio.
LMRI Yearly Shares OutstandingLMRI Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 2025 20M 40M 60M 80M
LMRI Yearly Total Debt VS Total AssetsLMRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 0.64, we must say that LMRI is in the distress zone and has some risk of bankruptcy.
  • LMRI's Altman-Z score of 0.64 is on the low side compared to the rest of the industry. LMRI is outperformed by 72.00% of its industry peers.
  • A Debt/Equity ratio of 1.45 is on the high side and indicates that LMRI has dependencies on debt financing.
  • LMRI has a worse Debt to Equity ratio (1.45) than 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.45
Debt/FCF N/A
Altman-Z 0.64
ROIC/WACC0.13
WACC10.55%
LMRI Yearly LT Debt VS Equity VS FCFLMRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that LMRI should not have too much problems paying its short term obligations.
  • LMRI's Current ratio of 1.27 is in line compared to the rest of the industry. LMRI outperforms 45.00% of its industry peers.
  • A Quick Ratio of 1.27 indicates that LMRI should not have too much problems paying its short term obligations.
  • The Quick ratio of LMRI (1.27) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
LMRI Yearly Current Assets VS Current LiabilitesLMRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. LMRI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.75% over the past year.
  • LMRI shows a small growth in Revenue. In the last year, the Revenue has grown by 7.82%.
EPS 1Y (TTM)50.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.47%
Revenue 1Y (TTM)7.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.95%

3.2 Future

  • The Earnings Per Share is expected to grow by 96.36% on average over the next years. This is a very strong growth
  • LMRI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.43% yearly.
EPS Next Y1427.58%
EPS Next 2Y349.32%
EPS Next 3Y178.88%
EPS Next 5Y96.36%
Revenue Next Year4.92%
Revenue Next 2Y5.26%
Revenue Next 3Y5.39%
Revenue Next 5Y5.43%

3.3 Evolution

LMRI Yearly Revenue VS EstimatesLMRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
LMRI Yearly EPS VS EstimatesLMRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 0 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

4

4. LMRI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LMRI. In the last year negative earnings were reported.
  • LMRI is valuated correctly with a Price/Forward Earnings ratio of 13.45.
  • 81.00% of the companies in the same industry are more expensive than LMRI, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of LMRI to the average of the S&P500 Index (22.12), we can say LMRI is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 13.45
LMRI Price Earnings VS Forward Price EarningsLMRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as LMRI.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 26.1
LMRI Per share dataLMRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • LMRI's earnings are expected to grow with 178.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y349.32%
EPS Next 3Y178.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LMRI Dividend Analysis

5.1 Amount

  • LMRI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LMRI Fundamentals: All Metrics, Ratios and Statistics

LUMEXA IMAGING HOLDINGS INC

NASDAQ:LMRI (4/27/2026, 8:00:00 PM)

Premarket: 9.6 -0.11 (-1.13%)

9.71

+0.11 (+1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26
Earnings (Next)N/A
Inst Owners30.69%
Inst Owner Change0.02%
Ins Owners1.65%
Ins Owner Change85.65%
Market Cap933.23M
Revenue(TTM)1.02B
Net Income(TTM)-47.10M
Analysts87.14
Price Target20.4 (110.09%)
Short Float %21.09%
Short Ratio4.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.5%
PT rev (3m)-11.5%
EPS NQ rev (1m)-27.41%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-9.82%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-1.44%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.45
P/S 0.91
P/FCF N/A
P/OCF 54.66
P/B 1.59
P/tB N/A
EV/EBITDA 26.1
EPS(TTM)-0.49
EYN/A
EPS(NY)0.72
Fwd EY7.44%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0.18
OCFY1.83%
SpS10.64
BVpS6.1
TBVpS-2.73
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -2.67%
ROE -8.04%
ROCE 1.69%
ROIC 1.33%
ROICexc 1.38%
ROICexgc 3.12%
OM 2.61%
PM (TTM) N/A
GM 15.4%
FCFM N/A
ROA(3y)-5.2%
ROA(5y)N/A
ROE(3y)-42.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.45
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 58.14%
Cap/Sales 2.29%
Interest Coverage 0.24
Cash Conversion 25.44%
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 0.64
F-Score7
WACC10.55%
ROIC/WACC0.13
Cap/Depr(3y)55.47%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.47%
EPS Next Y1427.58%
EPS Next 2Y349.32%
EPS Next 3Y178.88%
EPS Next 5Y96.36%
Revenue 1Y (TTM)7.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.95%
Revenue Next Year4.92%
Revenue Next 2Y5.26%
Revenue Next 3Y5.39%
Revenue Next 5Y5.43%
EBIT growth 1Y264.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.91%
EBIT Next 3Y27.19%
EBIT Next 5YN/A
FCF growth 1Y-149.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.08%
OCF growth 3YN/A
OCF growth 5YN/A

LUMEXA IMAGING HOLDINGS INC / LMRI Fundamental Analysis FAQ

What is the fundamental rating for LMRI stock?

ChartMill assigns a fundamental rating of 2 / 10 to LMRI.


What is the valuation status for LMRI stock?

ChartMill assigns a valuation rating of 4 / 10 to LUMEXA IMAGING HOLDINGS INC (LMRI). This can be considered as Fairly Valued.


What is the profitability of LMRI stock?

LUMEXA IMAGING HOLDINGS INC (LMRI) has a profitability rating of 1 / 10.


How financially healthy is LUMEXA IMAGING HOLDINGS INC?

The financial health rating of LUMEXA IMAGING HOLDINGS INC (LMRI) is 2 / 10.


What is the expected EPS growth for LUMEXA IMAGING HOLDINGS INC (LMRI) stock?

The Earnings per Share (EPS) of LUMEXA IMAGING HOLDINGS INC (LMRI) is expected to grow by 1427.58% in the next year.